The FLASCO Clinical Oncology Series: Antibody-Drug Conjugates (ADCs) is an advanced educational program designed to explore the groundbreaking role of antibody-drug conjugates in modern cancer therapy. This series will provide healthcare professionals with a comprehensive understanding of how ADCs are revolutionizing the treatment landscape, targeting cancer cells with precision while minimizing toxicity to healthy tissues. Focused on the science, clinical application, and evolving use of ADCs in oncology, the series will cover key topics such as the mechanisms of action, types of ADCs, clinical trial data, and the latest innovations in this field. Participants will learn about the development and utilization of ADCs for various cancers and will gain insights into the potential benefits and challenges of incorporating ADCs into cancer treatment regimens.
*Biopharmaceutical industry attendance is restricted to event sponsors only. For sponsorship information, please email katrina@flasco.org
